Kisspeptin-10 and Testosterone Research: HPG Axis, Male Reproductive Biology and Androgen Regulation UK 2026

Research Use Only. Not for human use. All content on this page relates strictly to preclinical and in vitro research findings.

Kisspeptin-10 — the biologically active C-terminal decapeptide fragment of the KISS1 gene product — is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, acting through kisspeptin receptor (KISS1R, formerly GPR54) on GnRH (Gonadotropin-Releasing Hormone) neurons in the hypothalamus to drive pulsatile GnRH secretion. While Kisspeptin-10 research has examined its roles in female reproductive biology extensively, its significance in male reproductive research — particularly HPG axis regulation of testosterone production, Leydig cell biology, and conditions of male hypogonadism — represents an equally important and mechanistically distinct research domain. This post examines Kisspeptin-10’s role in male reproductive endocrinology research.

The Male HPG Axis: GnRH Pulse Architecture and Testosterone Regulation

Testosterone production in the testes is regulated through a precise hormonal cascade: hypothalamic GnRH pulsatile secretion → anterior pituitary LH (Luteinising Hormone) release → Leydig cell LH receptor activation → steroidogenesis (cholesterol → pregnenolone → DHEA → androstenedione → testosterone via CYP11A1, CYP17A1, HSD3B and HSD17B enzymes). The pulsatility of GnRH — approximately one pulse per 60–90 minutes in adult males — is critical: continuous (non-pulsatile) GnRH receptor stimulation causes receptor downregulation and LH suppression, the mechanism exploited by GnRH agonists used in prostate cancer treatment to produce chemical castration.

Kisspeptin-10 sits at the top of this regulatory cascade, directly controlling the “GnRH pulse generator” in the hypothalamic arcuate nucleus (ARC). Kisspeptin neurons co-expressing neurokinin B (NKB) and dynorphin — collectively termed “KNDy neurons” — create an auto-regulatory oscillator: NKB drives kisspeptin neuron synchronisation and pulsatile activity, while dynorphin terminates each pulse. The result is precisely timed GnRH pulses that maintain physiologically appropriate LH and testosterone secretion. Kisspeptin-10 research in males thus directly interrogates this fundamental HPG regulatory mechanism.

Kisspeptin-10 and LH Pulse Research in Male Models

Rodent and ovine research has extensively characterised kisspeptin’s LH-stimulating effects in males. Intravenous or intracerebroventricular (ICV) Kisspeptin-10 administration produces robust, dose-dependent LH surges in male rodents, castrated rams, and non-human primates — effects abolished by GnRH receptor antagonist pre-treatment, confirming GnRH-mediated mechanism rather than direct pituitary action.

Pulsatile Kisspeptin-10 administration in male rodents and ovine models has been used to probe the HPG axis response characteristics: pulse frequency, amplitude, and GnRH receptor sensitisation dynamics. These studies have revealed important features of kisspeptin’s regulatory biology — including the desensitisation that occurs with continuous kisspeptin exposure (analogous to GnRH receptor downregulation with continuous GnRH) and the resensitisation that occurs during kisspeptin pulse intervals. Understanding these kinetics is fundamental to kisspeptin-based HPG research designs.

In male non-human primates, pulsatile intravenous Kisspeptin-10 administration maintains physiological LH and testosterone pulsatility over days to weeks of infusion — demonstrating the peptide’s capacity to sustain HPG axis activity through repeated administration protocols in primate research models.

Kisspeptin-10 and Hypogonadism Research Models

Male hypogonadism — characterised by reduced testosterone with secondary consequences for body composition, bone density, sexual function, mood and metabolic health — can arise from primary testicular failure (primary hypogonadism) or from impaired hypothalamic-pituitary function (secondary/hypogonadotrophic hypogonadism). Kisspeptin-10 research is particularly relevant to secondary hypogonadism models, where the defect lies in impaired GnRH/LH drive rather than intrinsic testicular failure.

Models of secondary hypogonadism relevant to Kisspeptin-10 research include:

• GnRH neuron-specific knockout models: Cre/lox-mediated ablation of GnRH neurons or KISS1R on GnRH neurons in mice produces infertility with severely reduced testosterone — a model of hypogonadotrophic hypogonadism that can be used to test kisspeptin rescue of HPG axis function
• Senescence-associated HPG decline: Aged male rodents show reduced hypothalamic kisspeptin expression, reduced GnRH pulse frequency, and declining testosterone — features of the “male andropause” (late-onset hypogonadism). Research has examined whether Kisspeptin-10 administration restores physiological LH and testosterone pulsatility in aged animals
• Diet-induced and stress-induced hypogonadism: Caloric restriction, obesity, and chronic stress all suppress HPG axis activity through distinct mechanisms (leptin deficiency, cortisol/CRH suppression of GnRH neurons). Research in these models examines whether kisspeptin can overcome HPG suppression imposed by metabolic or stress signals
• Opioid-induced hypogonadism: Chronic opioid exposure suppresses HPG axis activity through μ-opioid receptor effects on KNDy neurons (dynorphin upregulation suppresses kisspeptin pulsatility). Research has examined kisspeptin as a potential tool for studying HPG recovery in opioid-induced hypogonadism models

Testosterone Feedback and Kisspeptin Regulation

Testosterone negative feedback on the HPG axis operates in part through kisspeptin neurons, which express androgen receptors (AR). Testosterone and its metabolites (DHT via 5α-reductase, oestradiol via aromatase) suppress kisspeptin expression in arcuate nucleus KNDy neurons — reducing GnRH pulse frequency and amplitude — while oestradiol acts at preoptic area kisspeptin neurons to generate positive feedback in female models (relevant to LH surge biology). In males, the arcuate KNDy negative feedback loop is predominant.

This androgen-kisspeptin-GnRH feedback architecture has important implications for research design: castration removes testosterone feedback, producing dramatic increases in kisspeptin and GnRH pulse frequency and amplitude (the “castration response”), while testosterone replacement suppresses kisspeptin. Research examining how exogenous Kisspeptin-10 interacts with this feedback system — both in intact and castrated male animals — provides mechanistic insight into HPG feedback regulation that is directly relevant to clinical contexts including testosterone replacement therapy and fertility research.

Leydig Cell Biology and Steroidogenesis Research

Leydig cells in the testicular interstitium are the primary site of testosterone synthesis in males. LH binding to LH receptor (LHCGR) activates Gsα-cAMP-PKA signalling, which drives expression of StAR (steroidogenic acute regulatory protein) — the rate-limiting step for cholesterol import into the mitochondrial matrix where steroidogenesis initiates. Downstream enzymes (CYP11A1, CYP17A1, HSD3B2, HSD17B3) complete the conversion to testosterone.

Research examining whether Kisspeptin-10-driven LH increases translate into quantifiable Leydig cell steroidogenesis changes has used serum and testicular testosterone quantification (RIA, LC-MS/MS), StAR and steroidogenic enzyme mRNA expression (RT-PCR), and Leydig cell cholesterol ester accumulation (Oil Red O histology) as endpoints. The LH pulse amplitude and frequency produced by kisspeptin treatment critically determines the steroidogenic output, as continuous LH exposure desensitises LHCGR through receptor internalisation — a phenomenon directly relevant to kisspeptin research protocol design.

Spermatogenesis and Fertility Research

Beyond testosterone production, HPG axis integrity is essential for spermatogenesis — driven by FSH acting on Sertoli cells alongside testosterone acting locally within the seminiferous tubule. Research in GnRH-deficient models (hpg mice, KISS1R knockout mice) has demonstrated complete absence of spermatogenesis, which can be rescued by pulsatile GnRH or kisspeptin administration. This rescue research provides mechanistic proof that kisspeptin-driven GnRH pulsatility can restore not only testosterone but the full spermatogenic process.

Fertility endpoints used in male Kisspeptin-10 research include testicular weight and volume, seminiferous tubule cross-sectional area and spermatogenic cell layer thickness (H&E histology), sperm count and motility (CASA — computer-assisted sperm analysis), and successful mating/pregnancy rate in pairing experiments with wild-type females.

Summary for Researchers

Kisspeptin-10 male reproductive biology research operates through its fundamental role as the upstream HPG pulse generator regulator — driving GnRH pulsatility through KISS1R on arcuate nucleus KNDy neurons, which translates into LH surges, Leydig cell steroidogenesis and testosterone production. Research models include genetic HPG-deficient mice, aged hypogonadal rodents, metabolic/stress-induced HPG suppression, and opioid-induced hypogonadism — each providing distinct windows into kisspeptin’s regulatory biology. Testosterone negative feedback through androgen receptor-expressing KNDy neurons creates a self-regulating circuit whose dynamics are revealed by castration-rescue and replacement research designs. Spermatogenesis rescue in GnRH-deficient models confirms Kisspeptin-10’s capacity to restore full male reproductive function through upstream HPG stimulation. For researchers studying male hypogonadism, androgen deficiency biology, or HPG axis neuroendocrinology, Kisspeptin-10 provides a uniquely targeted entry point into the master regulatory switch of male reproductive biology.

Research Use Only — UK Regulatory Notice: Kisspeptin-10 is available for purchase in the United Kingdom for research and laboratory purposes only. It is not approved for human therapeutic use, is not a licensed medicinal product, and is not intended for use in clinical practice, human self-administration or veterinary treatment without appropriate regulatory authorisation. All research applications must comply with applicable UK legislation and institutional ethical oversight requirements.